Sunday, February 28, 2010

Are Hot Dogs From Kraft Foods and Sara Lee Choking Risk For Kids?

›
A new policy statement from the American Academy of Pediatrics (AAP), published in the February 22 online issue of Pediatrics , takes a clo...

First Solar Turns To New World for Solar Growth

›
In 2009, First Solar (FSLR-$105.90) generated almost 65 percent of its $2.06 billion in sales from German photovoltaic (PV) projects, from ...
Wednesday, February 24, 2010

Avoiding Cannibals at Johnson & Johnson

›
As patients with auto-immune disorders cycle through anti-TNF therapies and the failure pools increase, there is ample room for Johnson ...
Tuesday, February 23, 2010

Petrohawk Energy Promises Free Cash Flow By 2012

›
Petrohawk Energy (HK-$22.16) is nursing a mighty hangover after awaking from a 2 ½-year buying binge — $5 billion spent on acquiring leaseh...
Friday, February 19, 2010

Revlimid Keeps Celgene Healthy

›
Celgene (CELG-$60.11) chief executive Sol Barer predicts Revlimid will win regulatory approval as front-line treatment for newly diagnosed...
Wednesday, February 17, 2010

Southwest Airlines "Cop Out" in Kevin Smith Feud

›
Before backpedaling in a tweeted apology, Southwest Airlines (LUV-$12.29) insisted in a public retort that airline employees removed movie ...
Monday, February 15, 2010

Petrohawk Energy's Gas Reserve Valuations in Dispute

›
Petrohawk Energy’s (HK-$22.78) experienced significant growth in production and reserves in 2009, chairman and chief executive officer Floy...
Tuesday, February 09, 2010

Will Petro-Canada Acquisition Sink Suncor Energy?

›
Suncor Energy (SU-$30.05) is a long way from achieving the significant synergies envisioned from its all-stock C$19.63 billion acquisition ...
1 comment:
Sunday, February 07, 2010

Murphy Oil Spudding For Ethanol Prospects

›
Despite significantly weaker margins realized in 2009, Murphy Oil (MUR-$50.75) intends to add a combined 80 new gas stations to its networ...
Wednesday, February 03, 2010

McMoran Exploration: What's in Davy Jones' Locker?

›
Positive drilling results at its Davy Jones prospect could be a boom for McMoran Exploration (MMR-$16.80). The Gulf Coast energy company ha...
1 comment:
Sunday, January 31, 2010

Saving Trump Entertainment Resorts from the Trumps

›
Ivanka Trump and her father “The Donald” have allied with bondholders of bankrupt Trump Entertainment Resorts (TRMPQ-$0.08) , to compete wi...
1 comment:
Friday, January 29, 2010

Do Fifty CentiSeconds Justify Acorda Therapeutics' Oral MS Drug Approval by FDA?

›
Central to the Peripheral and CNS Drugs Advisory Committee’s review of Acorda Therapeutic’s (ACOR-$27.56) oral MS treatment Ampyra was whe...
1 comment:
Thursday, January 28, 2010

Why Cephalon's Nuvigil Patent-Infringement Challenges Could Backfire

›
The motive behind Cephalon's (CEPH-$65.00) recent patent-infringement lawsuits is clear: litigate to slow the market entrance of cheape...
1 comment:
Wednesday, January 27, 2010

On the Hunt for New MS Drugs: Big Pharma Eyes Acorda Therapeutics

›
When asked in an interview on the business channel CNBC today if its new oral treatment for MS, Ampyra , would cost between $5,000 to $10,00...

More Heartburn for Procter & Gamble's Prilosec OTC

›
For years Procter & Gamble (PG-$60.50) has reminded customers that its Prilosec OTC remedy effectively reduced heartburn-causing acid b...
1 comment:

Burger King Now Serving Up Beer With Those Whoppers

›
Exclusively at the Whopper Bar South Beach, Burger King (BKC-$17.60) customers can “Have it Their Way” and pair premium Whopper sandwiches ...
1 comment:
Monday, January 25, 2010

Innovation Key to Callaway Golf's Growth Prospects

›
Callaway Golf (ELY-$8.25) is the U.S. market leader (as either the No. 1 or No. 2 brand) in almost every equipment category. Management ack...
Sunday, January 24, 2010

Sixty Days and Counting for Somaxon Pharma's Silenor

›
Somaxon Pharmaceutical’s (SOMX-$2.40), acknowledgement of a Class 1 Response for its insomnia drug Silenor indicates a receptiveness by he...
Friday, January 22, 2010

Afrezza: Read the FDA Label!

›
MannKind Corp’s (MNKD-$10.32) inhaled insulin treatment Afrezza has been unable to outrun the long shadow of doubt cast by Exubera , the i...
1 comment:
Thursday, January 21, 2010

Abuse-Deterrent Opioids Best Medicines For What Ails King Pharmaceuticals

›
King Pharmaceuticals (KG-$13.00) will likely face generic intrusion for its popular muscle relaxant Skelaxin by 2012. With little visible ...